cyclic heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-11. Numbers and descriptions here follow the published literature rather than marketing material.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
CoA + acetyl-[acyl-carrier-protein] Thus, the two substrates of this enzyme are acetyl-CoA and acyl carrier protein, whereas its two products are CoA and acetyl-acyl-carrier-protein. This enzyme belongs to the family of transferases, specifically those acyltransferases transferring groups other than aminoacyl groups. The systematic name of this enzyme class is acetyl-CoA:[acyl-carrier-protein] S-acetyltransferase. Other names in common use include acetyl coenzyme A-acyl-carrier-protein transacylase, acetyl-CoA:ACP transacylase, [acyl-carrier-protein]acetyltransferase, [ACP]acetyltransferase, and ACAT. This enzyme participates in fatty acid biosynthesis.
=== Dentistry === As of 2019, the use of hydroxyapatite, or its synthetically manufactured form, nano-hydroxyapatite, is not yet common practice. Some studies suggest it is useful in counteracting dentine hypersensitivity, preventing sensitivity after teeth bleaching procedures and cavity prevention. Avian eggshell hydroxyapatite can be a viable filler material in bone regeneration procedures in oral surgery.
13 September Space - the Final Junkyard, about space debris; Nick Johnson of NASA; Paul Maley of United Space Alliance, and JSC Astronomical Society; Mark Mulrooney of the NASA Orbital Debris Observatory, and its liquid-mirror telescope; Scott J. Horowitz; Pam McCraw of Mission Operations Directorate at the Johnson Space Center in Texas; the Institute for Advanced Technology at the University of Texas at Austin; Richard Crowther of the Defence Evaluation and Research Agency; Don Kessler of NASA JSC; the French reconnaissance Cerise (satellite), which was damaged on 24 July 1996 by debris from Ariane; Darren McKnight and Kosmos 1275, launched on 4 June 1981, and was damaged on 24 July 1981; on 24 January 1978, the nuclear-powered Kosmos 954, a RORSAT, crashed into Canada; The Aerospace Corporation; the Russian Mars 96 was launched on 16 November 1996, to hopefully reach Mars on 12 September 1997, but re-entered the atmosphere east of Iquique in north Chile on 17 November 1997, carrying 270g of plutonium; as part of NASA's Systems for Nuclear Auxiliary Power, the satellite Transit 5BN-3 with a SNAP-9A nuclear power source, launched from Vandenberg Air Force Base (since May 2021, Vandenberg Space Force Base) in California, and never reached orbit on 21 April 1964, dispersing 1 kg of plutonium-238; the Iridium satellite constellation of 66 telecommunication satellites and the proposed Teledesic scheme; a damaged satellite could cause the catastrophic Kessler syndrome; John Muratore and the NASA X-38.
Cracking breaks larger molecules into smaller ones. This reaction requires heat and catalysts. The thermal cracking process follows a homolytic mechanism with formation of free radicals. The catalytic cracking process involves the presence of acid catalysts (usually solid acids such as silica-alumina and zeolites), which promote a heterolytic (asymmetric) breakage of bonds yielding pairs of ions of opposite charges, usually a carbocation. Carbon-localized free radicals and cations are both highly unstable and undergo processes of chain rearrangement, C–C scission in position beta (i.e., cracking) and intra- and intermolecular hydrogen transfer or hydride transfer. In both types of processes, the corresponding reactive intermediates (radicals, ions) are permanently regenerated, and thus they proceed by a self-propagating chain mechanism. The chain of reactions is eventually terminated by radical or ion recombination.
A typical bicycle chain (for derailleur gears) uses narrow 1⁄2-inch-pitch chain. The width of the chain is variable, and does not affect the load capacity. The more sprockets at the rear wheel (historically 3–6, nowadays 7–12 sprockets), the narrower the chain. Chains are sold according to the number of speeds they are designed to work with, for example, "10 speed chain". Hub gear or single speed bicycles use 1/2 x 1/8 inch chains, where 1/8 inch refers to the maximum thickness of a sprocket that can be used with the chain. Typically chains with parallel shaped links have an even number of links, with each narrow link followed by a broad one. Chains built up with a uniform type of link, narrow at one and broad at the other end, can be made with an odd number of links, which can be an advantage to adapt to a special chainwheel-distance; on the other side such a chain tends to be not so strong. Roller chains made using ISO standard are sometimes called "isochains".
Sources: en.wikipedia.org
He is often shown to get along well with and prefer to be with his cousin Amber rather than his sister Haddie because Amber, given her own personal struggles, has a greater understanding of his condition. Max develops a mentor relationship with Hank Rizzoli, developing an interest in photography. Hank and Max connect as they both deal with the struggles of living with Asperger's Syndrome. Max finds success in photography and sees it as a future career. Max struggles with mainstream middle school. During an overnight school trip, other students bully him and Adam and Kristina need to take him home early. In response, Kristina creates a charter school, Chambers Academy, for students with learning difficulties who do not respond to general or special education settings. Max graduates from Chambers Academy in the series finale.
=== Switch to IFCC units === The American Diabetes Association, European Association for the Study of Diabetes, and International Diabetes Federation have agreed that, in the future, HbA1c is to be reported in the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) units. IFCC reporting was introduced in Europe except for the UK in 2003; the UK carried out dual reporting from 1 June 2009 until 1 October 2011. Conversion between DCCT and IFCC is by the following equation:
Where a larger resolution indicates a better separation of peaks. This definition is used in a number of mass spectrometry texts. This use is also implied by the term "high-resolution mass spectrometry." A high value for resolution corresponding to good separation of peaks is similar to the convention used with chromatography separations, although the definitions are not the same. High resolution indicating better peak separation is also used in ion mobility spectrometry.
The vapor-compression cycle is used in most household refrigerators as well as in many large commercial and industrial refrigeration systems. Figure 1 provides a schematic diagram of the components of a typical vapor-compression refrigeration system. The thermodynamics of the cycle can be analyzed on a diagram as shown in Figure 2. In this cycle, a circulating refrigerant such as a low boiling hydrocarbon or hydrofluorocarbons enters the compressor as a vapour. From point 1 to point 2, the vapor is compressed at constant entropy and exits the compressor as a vapor at a higher temperature, but still below the vapor pressure at that temperature. From point 2 to point 3 and on to point 4, the vapor travels through the condenser which cools the vapour until it starts condensing, and then condenses the vapor into a liquid by removing additional heat at constant pressure and temperature. Between points 4 and 5, the liquid refrigerant goes through the expansion valve (also called a throttle valve) where its pressure abruptly decreases, causing flash evaporation and auto-refrigeration of, typically, less than half of the liquid. That results in a mixture of liquid and vapour at a lower temperature and pressure as shown at point 5. The cold liquid-vapor mixture then travels through the evaporator coil or tubes and is completely vaporized by cooling the warm air (from the space being refrigerated) being blown by a fan across the evaporator coil or tubes. The resulting refrigerant vapour returns to the compressor inlet at point 1 to complete the thermodynamic cycle.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.